Liver Fat Content in People with Pituitary Diseases: Influence of Serum IGF1 Levels.
Fiche publication
Date publication
avril 2018
Journal
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence, Pr PETIT Jean-Michel, Pr VERGES Bruno, Pr LOFFROY Romaric
Tous les auteurs :
Nguyen A, Ricolfi F, Lemogne B, Aho S, Lemaire S, Bouillet B, Duvillard L, Denimal D, Fourmont C, Loffroy R, Cercueil JP, Verges B, Petit JM
Lien Pubmed
Résumé
Non-alcoholic fatty liver disease (NAFLD) is commonly associated with obesity, metabolic syndrome, and type 2 diabetes. NAFLD is also seen in patients with endocrinopathies. However, the relationship between endocrine diseases and the development of NAFLD is not well known. In this study, we set out to determine whether liver fat content (LFC) was associated with IGF1 levels in people with pituitary diseases (PD). Eighty-nine patients with pituitary diseases and 74 healthy controls were included in this study. LFC was measured using MRI. Hepatic steatosis was defined as LFC>5.5%. Patients with PD were older, and had a higher BMI than healthy controls. LFC was significantly higher in people with PD than in controls (6.5% vs. 3.2%; p<0.001). LFC was negatively associated with the IGF1 level. The prevalence of steatosis was higher in PD patients than in controls (36.3% vs. 14.8%; p=0.002). In multivariate analysis, which included patients and controls, the predictive variables for steatosis were age, BMI and IGF1 levels, whereas the presence of pituitary diseases and gender were not associated with steatosis. Our data showed that LFC was strongly associated with IGF1 levels. These results suggest that steatosis associated with PD is probably a consequence of a low IGF1 level in these patients.
Mots clés
Adult, Biomarkers, blood, Body Mass Index, Case-Control Studies, Female, Humans, Insulin-Like Growth Factor I, analysis, Intra-Abdominal Fat, physiopathology, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, blood, Pituitary Diseases, complications, Prospective Studies
Référence
Horm. Metab. Res.. 2018 Apr;50(4):303-307